Luca Filippi is an Associate Professor of Nuclear Medicine with the Department of Biomedicine and Prevention at the University of Rome Tor Vergata, Rome, Italy. His research interests cover molecular and metabolic imaging, PET/SPECT, and targeted therapy, with a specific focus in recent years on multi-tracer imaging (18F-choline/18F-FACBC/PMSA-ligands) for the study of prostate carcinoma, applications of PET/CT with 18F-FDG in skin tumours undergoing treatment with immune checkpoint inhibitors, and applications of artificial intelligence and radiomics. Prof. Filippi is head of the AI/radiomics Study Group of the Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) and Editor-in-Chief of Expert Review of Medical Devices. He promotes academic and corporate teaching initiatives aimed at engaging youth in hybrid imaging, theranostics, and radiomics. His scholarly contributions include five book chapters and over 230 Scopus-indexed papers.
Luca Filippi is an Associate Professor of Nuclear Medicine with the Department of Biomedicine and Prevention at the University of Rome Tor Vergata, Rome, Italy. His research interests cover molecular and metabolic imaging, PET/SPECT, and targeted therapy, with a specific focus in recent years on multi-tracer imaging (18F-choline/18F-FACBC/PMSA-ligands) for the study of prostate carcinoma, applications of PET/CT with 18F-FDG in skin tumours undergoing treatment with immune checkpoint inhibitors, and applications of artificial intelligence and radiomics. Prof. Filippi is head of the AI/radiomics Study Group of the Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) and Editor-in-Chief of Expert Review of Medical Devices. He promotes academic and corporate teaching initiatives aimed at engaging youth in hybrid imaging, theranostics, and radiomics. His scholarly contributions include five book chapters and over 230 Scopus-indexed papers.